论文部分内容阅读
F30066系我国最新合成的一种非锑性抗血吸虫病药物.为观察其对急性血吸虫病退热效果和减轻服药反应,我站自1962年8月以来,采用了比一般用量为小的剂量,治疗了92例急性血吸虫病患者,现将结果报导如下. 临床资料 92例中男78例,女14例.7～15岁34例,16～25岁31例,26～35岁24例,36～45岁3例.入院前发热病程在一个月以内者75例,二个月以内者12例,二个月以上者3例,另有2例病史不详.治疗前体温在39℃以下者35例,39.1°～41℃57例.根据一般的临床分型方法,将全部病例分为轻型、中
F30066 is a new non-antimony anti-schistosomiasis drug synthesized in China.In order to observe the anti-schistosomiasis response to acute schistosomiasis and to reduce the medication response, we have used a smaller dosage than usual since August 1962 to treat A total of 92 patients with acute schistosomiasis, the results reported below.Clinical data 92 cases of male 78 cases, female 14 cases.Fracture of 7 to 15 years old in 34 cases, 16 to 25 years in 31 cases, 26 to 35 years in 24 cases, 36 ~ 45 years old in 3. Pre-admission fever duration of 75 months within one month, 12 patients within two months, more than two months in 3 cases, and another two cases of unknown history before treatment, body temperature below 39 ℃ in 35 cases , 39.1 ° ~ 41 ℃ 57 cases.According to the general clinical classification method, all cases were divided into light, medium